2 Information about olaparib

Marketing authorisation indication

2.1 Olaparib (Lynparza, AstraZeneca) as tablets is indicated 'as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy'.

Dosage in the marketing authorisation

2.2 Olaparib is taken orally. It is currently available both in a tablet and a capsule formulation. However, the capsule formulation is only licensed for people with a BRCA mutation and platinum-sensitive ovarian cancer and will be phased out when no longer needed by patients. Therefore, only the tablets are covered by this appraisal. The dosage of olaparib tablets is 300 mg (2×150-mg tablets) taken twice daily (600 mg per day).


2.3 The list price for olaparib tablets is £2,317.50 per 14-day pack; £4,635 per 28-day cycle (excluding VAT; British National Formulary online, accessed October 2018). The company has a commercial arrangement for olaparib tablets. The commercial arrangement additionally forms part of the managed access agreement for use of olaparib tablets in the Cancer Drugs Fund. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)